دورية أكاديمية
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
| العنوان: | Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study |
|---|---|
| المؤلفون: | Gaborit, B., Ancel, P., Abdullah, A., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M., Lasbleiz, A., Peiretti, F., Bornet, C., Lefur, Y., Pini, L., Rapacchi, Stanislas, Bernard, Monique, Resseguier, N., Darmon, P., Kober, F., Dutour, A. |
| المساهمون: | Hôpital de Niamey Niger, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), CIC-CPCET, Hôpital de la Timone CHU - APHM (TIMONE) |
| المصدر: | ISSN: 1475-2840 ; Cardiovascular Diabetology ; https://hal.inrae.fr/hal-03328849Test ; Cardiovascular Diabetology, 2021, 20 (1), ⟨10.1186/s12933-021-01237-2⟩. |
| بيانات النشر: | HAL CCSD BioMed Central |
| سنة النشر: | 2021 |
| المجموعة: | Aix-Marseille Université: HAL |
| مصطلحات موضوعية: | Ectopic fat, Myocardial energetics, Pcr/atp, Epicardial adipose tissue, SGLT2 inhibitors, SGLT2 inhibitors.Epicardial adipose tissue.Ectopic fat.Myocardial energetics.Pcratp.P-31-MRS.MRI, 31 P-MRS, MRI, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system |
| الوصف: | International audience ; Abstract Background Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We hypothesized that empaglifozin (EMPA) could modulate ectopic fat stores and myocardial energetics in high-fat-high-sucrose (HFHS) diet mice and in type 2 diabetics (T2D). Methods C57BL/6 HFHS mice ( n = 24) and T2D subjects ( n = 56) were randomly assigned to 12 weeks of treatment with EMPA (30 mg/kg in mice, 10 mg/day in humans) or with placebo. A 4.7 T or 3 T MRI with 1 H-MRS evaluation–myocardial fat (primary endpoint) and liver fat content (LFC)–were performed at baseline and at 12 weeks. In humans, standard cardiac MRI was coupled with myocardial energetics (PCr/ATP) measured with 31 P-MRS. Subcutaneous (SAT) abdominal, visceral (VAT), epicardial and pancreatic fat were also evaluated. The primary efficacy endpoint was the change in epicardial fat volume between EMPA and placebo from baseline to 12 weeks. Secondary endpoints were the differences in PCr/ATP ratio, myocardial, liver and pancreatic fat content, SAT and VAT between groups at 12 weeks. Results In mice fed HFHS, EMPA significantly improved glucose tolerance and increased blood ketone bodies (KB) and β-hydroxybutyrate levels ( p < 0.05) compared to placebo. Mice fed HFHS had increased myocardial and liver fat content compared to standard diet mice. EMPA significantly attenuated liver fat content by 55%, ( p < 0.001) but had no effect on myocardial fat. In the human study, all the 56 patients had normal LV function with mean LVEF = 63.4 ± 7.9%. Compared to placebo, T2D patients treated with EMPA significantly lost weight (− 2.6 kg [− 1.2; − 3.7]) and improved their HbA1c by 0.88 ± 0.74%. Hematocrit and EPO levels were significantly increased in the EMPA group compared to placebo ( p < 0.0001, p = 0.041). EMPA significantly increased glycosuria and plasma KB levels compared to placebo ( p < 0.0001, p = 0.012, respectively), and ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33648515; hal-03328849; https://hal.inrae.fr/hal-03328849Test; https://hal.inrae.fr/hal-03328849/documentTest; https://hal.inrae.fr/hal-03328849/file/s12933-021-01237-2.pdfTest; PUBMED: 33648515; WOS: 000625382600001 |
| DOI: | 10.1186/s12933-021-01237-2 |
| الإتاحة: | https://doi.org/10.1186/s12933-021-01237-2Test https://hal.inrae.fr/hal-03328849Test https://hal.inrae.fr/hal-03328849/documentTest https://hal.inrae.fr/hal-03328849/file/s12933-021-01237-2.pdfTest |
| حقوق: | http://creativecommons.org/licenses/byTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.3AA33246 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1186/s12933-021-01237-2 |
|---|